Jonathan Tegge
2023
In 2023, Jonathan Tegge earned a total compensation of $2.1K as Former Interim Chief Financial Officer at InMed Pharmaceuticals.
Compensation breakdown
| Option Awards | $2,100 |
|---|---|
| Total | $2,100 |
Tegge received $2.1K in option awards, accounting for 100% of the total pay in 2023.
Rankings
In 2023, Jonathan Tegge's compensation ranked 2,971st out of 2,983 executives tracked by ExecPay.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,971 out of 2,983 | 0th |
Division Manufacturing | 1,633 out of 1,637 | 0th |
Major group Chemicals And Allied Products | 904 out of 906 | 0th |
Industry group Drugs | 867 out of 869 | 0th |
Industry Pharmaceutical Preparations | 625 out of 627 | 0th |
Source: SEC filing on October 28, 2024.
Tegge's colleagues
We found four more compensation records of executives who worked with Jonathan Tegge at InMed Pharmaceuticals in 2023.
2023
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
2023
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
2023
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
2023
Eric Hsu
InMed Pharmaceuticals